THC THERAPEUTICS INC - THCT STOCK NEWS

THC Therapeutics, Inc. (THCT) has secured an agreement with Shefford Capital Partners for up to $50 million in funding aimed at acquisitions in the cannabis and alternative therapies sectors. The deal includes $25 million in restricted shares and $25 million in debt financing. This capital will support THCT's strategy to acquire established companies within the cannabis industry and modern healthcare. The favorable terms, akin to those available to larger market-listed firms, mark a significant advancement for THCT and its mission to become a leader in cannabis and health-related mergers and acquisitions.

THC Therapeutics, Inc. (THCT) has appointed Jonathan Cross as the new Chief Financial Officer, leveraging his 33 years of experience in finance and mergers and acquisitions. Cross aims to enhance shareholder value and develop a finance team focused on transparency and accountability. He plans to refine the company's strategy, including the ongoing development of the dHydronator, a device that accelerates cannabis drying. Under CEO Brandon Romanek, the company is also exploring entry into the psychedelics market, aiming to solidify its position in the cannabis industry.

THC Therapeutics, Inc. (THCT) is considering entering the precious metals sector by establishing a subsidiary named THCT Silver for online retail of silver bullion. The company has been accumulating silver since February 2021 and aims to sell silver to publicly traded companies, providing them an opportunity to diversify cash holdings. CEO Brandon Romanek, with over 15 years of experience, believes that this strategy addresses market manipulation and fosters demand for silver. The strategy is a potential revenue growth avenue, leveraging increasing retail interest in silver.

THC Therapeutics (THCT) has signed a contract with Dr. Jesse Dean to onboard well-known cannabis celebrities to its board of directors. This agreement aims to enhance THC Therapeutics' marketing strategy for its dHydronator technology. Dr. Dean's contract includes 2.3 million shares and warrants that could generate $4.5 million if exercised. CEO Brandon Romanek expresses enthusiasm about the potential celebrity partnerships that Dr. Dean can bring. The dHydronator aims to revolutionize cannabis drying, significantly reducing drying time from 10-14 days to under 14 hours.

THC Therapeutics, Inc. (THCT) has completed the design phase for the consumer model of its patented dHydronator®. This product, aimed at the cannabis market, significantly reduces drying time from two weeks to less than 14 hours while sanitizing the product. The company is now seeking manufacturing partners and is in the pre-production phase. THC Therapeutics plans to enhance its patent claims as the commercial model design progresses. CEO Brandon Romanek emphasizes the importance of this step as they engage with strategic partners for future growth.

THC Therapeutics, Inc. (THCT) has finalized the consumer model design for its patented dHydronator®, a cannabis sanitizing dryer, now entering rapid prototyping for mass manufacturing. Following extensive market research by Keyhole Research, the company has also initiated the search for a manufacturing partner. The dHydronator® can reduce cannabis drying time to 10-14 hours while sanitizing the product efficiently, validated through independent testing. Additionally, the company aims to expand its patent protections and develop a commercial model of the device.

THC Therapeutics, Inc. (THCT) announced its partnership with Milestone Management Services to enhance corporate communications and investor awareness. Milestone's CEO emphasized the growing investor interest in sectors like cannabis and technology. Brandon Romanek, CEO of THCT, highlighted that this collaboration will improve deal flow and capital raising efforts. The company is leveraging its patented dHydronator technology, which significantly reduces cannabis drying time, and is actively seeking strategic partnerships to increase shareholder value.

THC Therapeutics, Inc. (THCT) has successfully acquired significant amounts of physical silver at a low premium above spot price, leveraging the Founder & Chairman’s extensive experience in the precious metals market.

Brandon Romanek, with 15 years in the industry, emphasized the opportunity to purchase physical silver amid market manipulation by major banks. The company aims to increase its holdings, anticipating a shift towards physical silver trading. This acquisition aligns with THCT's strategy to enhance its precious metals and digital currency assets, positioning the firm well in the evolving market.

THC Therapeutics, Inc. (THCT) has joined the Las Vegas Medical Marijuana Association (LVMMA) to enhance its growth strategy by leveraging connections within the cannabis industry. The company plans to raise up to $75 million through a Reg A+ offering to fund its expansion. CEO Parker Mitchell expressed enthusiasm about the opportunities this association will bring. THC Therapeutics focuses on the dHydronator®, a technology that significantly reduces cannabis drying time from 10-14 days to less than 14 hours, while also exploring partnerships in cannabis-testing and wellness sectors.